Promoter Amit Mahendra Sanghvi has submitted a revised disclosure to BSE Limited regarding his recent share disposal in Shaily Engineering Plastics Limited . The revision, dated December 16, 2025, addresses discrepancies identified by the exchange's listing compliance team regarding the mode of disposal for his earlier transaction.

Disclosure Correction Details

Sanghvi had originally submitted a disclosure on November 15, 2025, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following his disposal of 1,00,000 equity shares. However, BSE's listing compliance team identified that the mode of acquisition/sale was not properly specified in the original filing.

Transaction Specifics

The revised disclosure confirms that the disposal of 1,00,000 shares was conducted through open market sale on November 4, 2025. This transaction resulted in a reduction of Sanghvi's shareholding from 2.84% to 2.62% of the company's total share capital.

Shareholding Structure Impact

The disposal represents a minor adjustment in the promoter's stake, with Sanghvi maintaining his position as a significant stakeholder in the company. The total equity share capital of Shaily Engineering Plastics remains at ₹9.19 crores, comprising 4,59,55,093 equity shares of ₹2 each.

Regulatory Compliance

The submission of the revised disclosure demonstrates adherence to regulatory requirements under SEBI's substantial acquisition and takeover regulations. The correction ensures complete transparency regarding the nature of the share disposal transaction, providing clarity to market participants and regulatory authorities.

This administrative correction maintains the accuracy of corporate disclosures while ensuring compliance with exchange listing requirements and SEBI regulations governing substantial shareholding changes.

Shaily Engineering Plastics Limited (SEPL) has reported strong financial results for the second quarter of fiscal year 2026, demonstrating significant growth and expansion in its healthcare segment. The company's strategic focus on innovative drug delivery devices, particularly for GLP-1 medications, has driven its performance.

Financial Highlights

• Revenue grew by 34% year-on-year to INR 257.00 crores in Q2 FY26
• EBITDA doubled to INR 82.00 crores, with margins expanding by 1,030 basis points to 31.80%
• Profit After Tax (PAT) increased by 134% to INR 51.00 crores, with margins improving by 860 basis points to 20.00%

Segment Performance

The healthcare segment has shown remarkable growth, now contributing 38% to the overall revenue mix, doubling from the previous year.

Operational Highlights

• SEPL processed 6,652 tons of polymers in Q2 FY26, a 7.5% increase from Q2 FY25
• Machine utilization rate stands at 48% in both Q2 and H1 FY26
• Exports accounted for 68% of total revenue in Q2 FY26

Strategic Developments

Healthcare Segment Expansion

• Launched next-generation GLP-1 device, Shaily Axiom Max
• Signed four new projects across GLP-1 and other therapies
• Installed 19 new machines at manufacturing facilities

Capacity Expansion

• Increasing pen manufacturing capacity from 40 million to 80 million units by end of FY26
• Investing approximately INR 125.00 crores for capacity expansion in FY26

Consumer Segment

• Awarded 5 new projects from 3 marquee home furnishings customers

Industrial Segment

• Secured 1 new project from an automotive major

Consumer Electronics

• Expected to begin revenue generation in H2 FY26

Future Outlook

• Healthcare segment projected to grow at over 30-40% annually for the next few years
• Exploring opportunities in semiconductor business
• Potential for significant growth in Consumer Electronics segment by FY28

Amit Sanghvi, Managing Director of SEPL, commented on the results: "We have delivered strong revenue growth of 34% to INR 257.00 crores on a year-on-year basis, with EBITDA margins expanding by over 1,000 basis points to 31.80%. The growth is attributable to improved traction in our Healthcare segment, which showed a growth of 163% on a year-on-year basis to INR 98.60 crores."

The company's focus on innovation and expansion in the healthcare segment, particularly in drug delivery devices for GLP-1 medications, positions it well for continued growth. With ongoing capacity expansion and new product developments, Shaily Engineering Plastics appears poised for sustained performance in the coming years.

Investors should note that while the company's growth trajectory is impressive, market conditions and regulatory approvals, especially in international markets like Canada, may impact future performance. The management remains optimistic about the company's prospects across its diverse business segments.